Speciality
Spotlight

 




 


Oncology


 

 





Transfusion
Medicine

  

  • Wandt
    H, Frank M, Ehninger G, et al [ Inst of Medical Oncology
    and Hematology, Nurnberg, Germany; Med School Hannover,
    Germany; Technical Univ Dresden, Germany ]

    Safety and Cost Effectiveness of a 10  * 109/L
    Trigger for Prophylactic Platelet Transfusions Compared
    with the Traditional 20 * 109/L Trigger : A
    Prospective Comparative Trial in 105 Patients with Acute
    Myeloid Leukemia


    Blood 91: 3601-3606, 1998

     

    This study compares two groups of patients group A
    [n=58] were transfused at a morning platelet level of 10
    * 109/L, and group B [n=47] at a level of
    platelet 20 * 109/L. The cost of platelet
    therapy was one-third lower for group A than for group
    B, bleeding risks were not increased. The editor
    comments that by keeping the lower threshold for
    platelet transfusion combined with measures such as
    leukocyte filtration and ultraviolet irradiation to
    prevent alloimmunization and development of
    refractoriness will improve the utility of prophylactic
    transfusions to prevent bleeding and lower the cost.

       

  • Barosi
    G, Marchetti M, Liberato NL [ IRCCS Policlinico S Matteo,
    Pavia, Italy ]


    Cost-effectiveness of Recombinant Human Erythropoietin
    in the Prevention of Chemotherapy-induced Anaemia



    Br J Cancer 78: 781-787, 1998


      

    Chemotherapy induced anemia responds to recombinant
    human erythopoirtin [ rHuEPO ] however the dosage
    required high 150 u/kg subcutaneous three times a week
    for 4 months, reduced, the probability of transfusions
    from 21.9% to 10.4% and the numbers of RBC units per
    patient per month from 0.55 to 0.29. As per the data
    available in this study rHuEPO is not cost effective for
    treatment of chemotherapy induced anemia. The editor
    comments that the certain gains by without blood
    transfusion is difficult to ascertain these are the
    improved quality of life, the inconvenience associated
    with blood transfusion and the risk of HIV or hepatitis
    C virus.

         


 

 



 

 

Speciality Spotlight

 

 

Transfusion Medicine
  

  • Wandt H, Frank M, Ehninger G, et al [ Inst of Medical Oncology and Hematology, Nurnberg, Germany; Med School Hannover, Germany; Technical Univ Dresden, Germany ]
    Safety and Cost Effectiveness of a 10  * 109/L Trigger for Prophylactic Platelet Transfusions Compared with the Traditional 20 * 109/L Trigger : A Prospective Comparative Trial in 105 Patients with Acute Myeloid Leukemia
    Blood 91: 3601-3606, 1998
     
    This study compares two groups of patients group A [n=58] were transfused at a morning platelet level of 10 * 109/L, and group B [n=47] at a level of platelet 20 * 109/L. The cost of platelet therapy was one-third lower for group A than for group B, bleeding risks were not increased. The editor comments that by keeping the lower threshold for platelet transfusion combined with measures such as leukocyte filtration and ultraviolet irradiation to prevent alloimmunization and development of refractoriness will improve the utility of prophylactic transfusions to prevent bleeding and lower the cost.
       

  • Barosi G, Marchetti M, Liberato NL [ IRCCS Policlinico S Matteo, Pavia, Italy ]
    Cost-effectiveness of Recombinant Human Erythropoietin in the Prevention of Chemotherapy-induced Anaemia
    Br J Cancer 78: 781-787, 1998
      
    Chemotherapy induced anemia responds to recombinant human erythopoirtin [ rHuEPO ] however the dosage required high 150 u/kg subcutaneous three times a week for 4 months, reduced, the probability of transfusions from 21.9% to 10.4% and the numbers of RBC units per patient per month from 0.55 to 0.29. As per the data available in this study rHuEPO is not cost effective for treatment of chemotherapy induced anemia. The editor comments that the certain gains by without blood transfusion is difficult to ascertain these are the improved quality of life, the inconvenience associated with blood transfusion and the risk of HIV or hepatitis C virus.
         

 

 

 

By |2022-07-20T16:43:57+00:00July 20, 2022|Uncategorized|Comments Off on Transfusion Medicine

About the Author: